Last updated on February 2018

A Trial With Metronomic Low-dose Treosulfan Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC


Brief description of study

This is a Phase II, multicentre, open-label, randomized, and controlled study, evaluating the efficacy and safety of combined modularized treatment of treosulfan, pioglitazone and clarithromycin in patients with with squamous and non- squamous cell lung cancer, respectively after platin failure.

Detailed Study Description

Patients will be randomized 1:1, and will be stratified according to histology (squamous cell carcinoma vs adenocarcinoma).

86 patients with platin refractory Non-Small Cell Lung Cancer (NSCLC) will be treated either with metronomic low-dose treosulfan, pioglitazone and clarithromycin (experimental arm) or with nivolumab (squamous cell lung cancer and nonsquamous cell lung cancer).

Patients will undergo tumor assessments at baseline and every 6 weeks (approximately every two cycles) thereafter, until progression. Patients without progression after 36 weeks will undergo tumor assessments every 12 weeks.

Clinical Study Identifier: NCT02852083

Contact Investigators or Research Sites near you

Start Over

Susanne Recker

St. Antonius-Hospital
Eschweiler, Germany
9.53miles
  Connect »